+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Translational Glycobiology in Human Health and Disease

  • ID: 5008002
  • Book
  • September 2020
  • Region: Global
  • 480 Pages
  • Elsevier Science and Technology
1 of 3

Along with nucleic acids, proteins, and lipids, carbohydrates stand as one of four main components of cellular architecture. However, glycobiology (or carbohydrate bioscience) is little understood by non-experts, partly because carbohydrates are a complex, diverse class of molecules structurally and functionally. In recent years, advances in computational analytics (glycomics) have allowed us to better interpret and realize the importance of glycobiology in human health and disease, and glycans and their associated processes have been shown to play a significant role across a variety of disease types. As the biomedical sciences continue to adopt multi-omic and precision medicine approaches, a greater understanding of glycobiology is essential for maintaining healthy physiology and advancing disease treatment.

Translational Glycobiology in Human Health and Disease offers a deep examination of glycobiology for experts and non-experts alike in areas ranging from the role of glycobiology in chronic and infectious diseases to advances in technologies for higher throughput analysis and diagnosis. While keeping human health in the forefront, this book integrates a thorough discussion of glycobiology fundamentals with its growing areas of application and societal impact. With emphasis throughout on the interdisciplinary nature of glycosciences, this book also features perspectives from the health, computational (glycoanalytics), materials, biopharmaceutical, and diagnostic sciences.

Disease and speciality areas addressed include gycoimmunology, neuroglycobiology, commensal glycobiology, gut health, regenerative medicine and glycobiology, glycobiology and cancer, congenital disorders of glycosylation, infectious disease glycobiology, and parasite glycobiology. Computational approaches discussed, supporting the advance of new research, include advanced glycoanalytics, glycomics microarrays, glycoengineering, and glycol systems biology. Additionally, authors consider impact areas for society and public health, such as glycobiology and entrepreneurship, policy and regulatory requirements for glycosylation, future research, and translation to new diagnostics and drug discovery.

  • Provides a deep, foundational overview of glycoscience and its translational potential, highlighting glycobiology's growing role in human health and disease study
  • Examines a broad range of relevant disease areas and applications of glycobiology in policy and public health
  • Features chapter contributions from leading, international experts in the field, fully integrating perspectives from the health, computational, materials, biopharmaceutical, and diagnostic sciencess
Note: Product cover images may vary from those shown
2 of 3

1. Introduction

Section 1: Glycobiology 2. Carbohydrates and human glycosylation 3. Carbohydrate-binding proteins 4. Carbohydrate-active enzymes

Section 2: Glycobiology and health 5. Glycoimmunology 6. Neuroglycobiology 7. Commensal glycobiology and gut health 8. Microbiota accessible carbohydrates and the gut microbiome 9. Regenerative medicine and glycobiology 10. Exosome glycosylation for signalling and function

Section 3: Glycobiology and disease 11. Cancer  12. Altered glycosylation in autoimmune diseases 13. Metabolic diseases: Disorders of carbohydrate metabolism and lysosomal storage 14. Congenital Disorders of Glycosylation 15. Microbial infectious disease glycobiology 16. Parasite glycobiology 17. Glycobiology of neurodegenerative diseases  18. Glycobiology of neural injury and regeneration

Section 4: Glycotechnologies 19. Diagnostics and novel carbohydrate recognition molecules 20. Advanced glycoanalytics 21. Glycomics microarrays 22. Glycoengineering and systems biology 23. Computational Glycobiology 24. Carbohydrate-incorporated Biomaterials

Section 5: Glycobiology and Society 25. Translational glycobiology and entrepreneurship for health 26. Glycobiology: Public engagement and society 27. Policy and regulatory requirements for glycosylation  28. Public health and translational glycobiology 29. Future perspectives/ summary

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Kilcoyne, Michelle
Dr. Michelle Kilcoyne is Lecturer in Glycosciences at the National University of Ireland Galway. Dr. Michelle Kilcoyne completed her PhD in analytical carbohydrate chemistry in the School of Chemistry at NUI Galway in 2004, specialising in structural analysis of bacterial polysaccharides. She then took up a postdoctoral position in Arizona State University where she further specialised in mass spectrometry and HPLC, as well as expanding her interests to mammalian glycosylation. She returned as a postdoctoral researcher to NUI Galway in 2007 working on industry-supported and European projects, developing high throughput platforms for carbohydrate profiling. In 2014 Dr. Kilcoyne was appointed Lecturer in Glycosciences, is currently a member of Discipline of Microbiology at NUI Galway and leads the Carbohydrate Signalling Group. She is the recipient of a Royal Society of Chemistry Analytical Chemistry Trust Fund Fellowship for 2018. Her main interests are in glycoanalytics, novel glycomics platform development and carbohydrate-mediated host-microbe interactions.
Joshi, Lokesh
Prof. Lokesh Joshi is Director of the Advanced Glycoscience Research Cluster and leader of the Glycoscience Group at NUI Galway, a Co-Director of CÚRAM, a medical device centre, and the Vice-President for Research at NUI Galway. His principal focus of research is in understanding the roles of glycans and lectins in health and diseases and developing novel technologies for glycomics. Prof. Joshi has been involved in two spin out companies, Arizona Engineered Therapeutics (AzERx) and Aquila Biosciences. The NIH and VC sources funded AzERx to develop peptide-based therapeutics for vascular applications and AzERx was acquired by Orthologic (Now Capstone Therapeutics) in 2006. Aquila Bioscience is a healthcare company working on various projects funded by EI, EU, European Defence Agency and private industries. Prof. Joshi is an SFI-Stokes Professor of Glycosciences and the Irish representative on European Universities Association's Research Programme Working group.
Note: Product cover images may vary from those shown
Adroll
adroll